Study says fibre provides pain relief
25/06/2009
A medical journal in the US has published details of a clinical study that supports the claims of Holofiber specialist Hologenix that its Celliant product reduces pain.
Clothing made from Holofiber has been around for a number of years, but even early adopters said that medical evidence to support its claims would be essential if the invention was to make a big impact on the market.
Celliant, which in recent years has gone into products such as specialist socks for the sports and healthcare markets, can enhance oxygen levels in the body, aiding in comfort, healing, performance and overall wellness.
The new clinical study was carried out by research scientists affiliated to University of California Irvine Healthcare Center. Their findings show that the material also has potent pain relief capabilities. In a double blind study using measurement techniques successfully employed in government-approved clinical trials of pain relief medications, the magnitude of pain relief reported by participants using products enhanced with Celliant was significantly greater than that reported by participants using placebo products.
"We have completed a properly designed clinical trial which shows strong results in favour of Celliant," said Seth Casden, Hologenix chief executive. "The results are statistically significant, providing clinical proof that products enhanced with Celliant actually reduce pain."
The technology behind Celliant is based on years of research regarding the effect of certain wavelengths of light on the body and wound healing. Past studies have shown that light can be used to reduce pain, speed healing, increase energy and improve overall wellness. Celliant is a polymer fibre containing optically active micro-particles, a proprietary mixture of natural materials, which scatter and reflect visible and near infrared light. Products constructed with such optically modified fibers are designed to scatter and reflect light and energy onto the underlying tissue and skin.
Share this story:
